02:35 PM EDT, 07/30/2024 (MT Newswires) -- Labcorp ( LH ) said Tuesday it is expanding its collaboration with Ultima Genomics to explore new whole genome sequencing clinical applications, including molecular residual disease in patients with early-stage solid tumor cancers.

Labcorp ( LH ) said it plans to use Ultima's UG 100 platform and ppmSeq technology, which, combined with its own Plasma Detect, have shown in preliminary data the ability to detect rare variants at extremely low limits, improved sensitivity and specificity, and more efficient, scalable and cost-effective workflows.

Price: 212.92, Change: +2.17, Percent Change: +1.03